MELVILLE, N.Y.–(BUSINESS WIRE)–Responding to the growing need for dedicated ophthalmic image management software that is easy to use and can enhance office workflow, while also keeping security and compliance with CMS and HIPAA regulations in mind, C…
Kids Decrease Risk of Myopia With More Time Outside (CME/CE)
(MedPage Today) — Organized outdoor activities show results in randomized trial
Uncategorized
InSite Vision terminates QLT bid, plans to merge with Sun Pharma
InSite Vision terminated a merger agreement with QLT and accepted a merger bid from Sun Pharmaceutical.The all-cash acquisition is valued at $0.35 per share, or approximately $48 million in aggregate equity value, on a fully diluted basis, according to…
AACR-Sponsored Poll Criticized for ‘Priming’
(MedPage Today) — Survey may have stacked deck in bid to sway Congress on research funding
Uncategorized
Publication Exclusive: Fallout from failed clinical trials poses challenges to companies
So far in 2015, four different ophthalmic products in phase 3 clinical trials failed to meet their primary endpoints. Ocular Surgery News spoke with three of these companies to find out what happened and how they responded. Their stories offer a telling glimpse at the challenges and opportunities companies face when endpoints are missed in clinical trials as part of the overall innovation cycle.“Private companies often simply learn from their experience and make appropriate adjustments to their research and business plan. They continue on as long as their investors are optimistic they will eventually create value,” OSN Chief Medical Editor Richard L. Lindstrom, MD, said. “Public companies must disclose any material event in a timely fashion and usually see a significant fall in their share price, usually in the 20% to 50% range, but it can be even more if it is an FDA trial not approved by a panel.”
NovaBay Pharmaceuticals Signs Agreement with Nation’s Second Largest Independent Optometry Group, ALLDocs
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that the company’s prescription daily eyelid and lash hygiene product Avenova™ will be marketed through ALLDocs Optometry Group, making the product available to the group’s optometrists. ALLDocs, also known as The Association of LensCrafters Leaseholding Doc